Abstract:Myotonic dystrophy (DM) is a genetic disorder featured by muscular dystrophy. It is caused by CUG expansion in the myotonic dystrophy protein kinase gene that leads to aberrant signaling and impaired myocyte differentiation. Many studies have shown that microRNAs are involved in the differentiation process of myoblasts. The purpose of this study was to investigate how the miR-322/miR-503 cluster regulates intracellular signaling to affect cell differentiation. The cell model of DM1 was employed by expressing GFP-CUG200 or CUGBP Elav-like family member 1 (Celf1) in myoblasts. Immunostaining of MF-20 was performed to examine myocyte differentiation. qRT-PCR and western blot were used to determine the levels of Celf1, MyoD, MyoG, Mef2c, miR-322/miR-503, and mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK/ERK) signaling. Dual luciferase assay was performed to validate the interaction between miR-322/miR-503 and Celf1. CUG expansion in myoblasts impaired the cell differentiation, increased the Celf1 level, but it decreased the miR-322/miR-503 levels. miR-322/miR-503 mimics restored the impaired differentiation caused by CUG expansion, while miR-322/miR-503 inhibitors further suppressed. miR-322/miR-503 directly targeted Celf1 and negatively regulated its expression. Knockdown of Celf1 promoted myocyte differentiation. Further, miR-322/miR-503 mimics rescued the impaired differentiation of myocytes caused by CUG expansion or Celf1 overexpression through suppressing of MEK/ERK signaling. miR-322/miR-503 cluster recover the defective myocyte differentiation caused by RNA-toxic via targeting Celf1. Restoring miR-322/miR-503 levels could be an avenue for DM1 therapy.

The Rna-Binding Protein Cugbp1 Regulates Stability of Tumor Necrosis Factor Mrna in Muscle Cells - Implications for Myotonic Dystrophy

CUG repeat RNA-dependent proteasomal degradation of MBNL1 in a cellular model of myotonic dystrophy type 1

Treatment of Type 1 Myotonic Dystrophy by Engineering Site-specific RNA Endonucleases that Target (CUG)n Repeats

Phase-separated stress granules and processing bodies are compromised in Myotonic Dystrophy Type 1

Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1

Aberrant Myokine Signaling in Congenital Myotonic Dystrophy

Myotonic Dystrophy: Evidence for a Possible Dominant-Negative RNA Mutation

rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences

Condensation properties of stress granules and processing bodies are compromised in myotonic dystrophy type 1

Celf1 Regulates Cell Cycle and is Partially Responsible for Defective Myoblast Differentiation in Myotonic Dystrophy RNA Toxicity.

Reversible cardiac disease features in an inducible CUG repeat RNA–expressing mouse model of myotonic dystrophy

Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein with high affinity for expanded CUG repeats

Small Molecule Screening Identifies HSP90 as a Modifier of RNA Foci in Myotonic Dystrophy Type 1

HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy.

Altered drug metabolism and increased susceptibility to fatty liver disease in a mouse model of myotonic dystrophy

Mir-322/Mir-503 Clusters Regulate Defective Myoblast Differentiation in Myotonic Dystrophy RNA-toxic by Targeting Celf1.

Identification of ZNF850 as a novel CTG repeat expansion-related gene in myotonic dystrophy type 1 patient-derived iPSCs

Molecular genetics of congenital myotonic dystrophy

Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1

Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model

Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing